Pacira Pharma (PCRX) Tops Q2 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update
August 6, 2020 8:00 AM EDT-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 ---- Conference call today at 8:30 a.m. ET --
PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today reported financial results for the second quarter of 2020.
We are very pleased to report that since the peak of the impact from COVID-19 in April, weve seen a steady and continued increase in EXPAREL sales. This is a testimony to the resolve... More
